COMMUNIQUÉS West-GlobeNewswire

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
11/08/2026
Prescription Drug User Fee Act target action date is February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for Stargardt Disease Type 1 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite [...]
Stereotaxis Reports 2026 Second Quarter Financial Results & Business Updates
11/08/2026
Robotic catheter revenue surpasses $1M in the quarter, growing 270% sequentially First GenesisX robotic system purchase by US hospital to be installed this fall Multiple Synchrony digital operating room systems sold and [...]
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08/2026
Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film Remains on track to resubmit Anaphylm NDA to the FDA in Q3 2026 Continues pre-launch [...]
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
11/08/2026
Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027 [...]
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11/08/2026
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway [...]
ASHA Names 2026 Media Champion Award Recipients
11/08/2026
Rockville, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The American Speech-Language-Hearing Association (ASHA) announced the recipients of ASHA’s 2026 Media Champion Awards today. These awards recognize media outlets, ASHA [...]
Rampart Withdraws Appeal of USPTO’s Invalidation Decision
11/08/2026
ST. PAUL, Minn., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Egg Medical announced today that Rampart IC, LLC (“Rampart”) withdrew its appeal of the USPTO’s reexamination decision that the claims of Rampart’s U.S. Patent No. 11, [...]
Five Years of Unprecedented Growth: TimelyCare Redefines Student Well-Being
11/08/2026
Latest Inc. 5000 ranking cements TimelyCare’s position as a trusted, high-impact partner for educational communities. Fort Worth, TX, Aug. 11, 2026 (GLOBE NEWSWIRE) -- TimelyCare, education’s most trusted virtual care [...]
NovelMed Advances NM5072 for Multiple Ocular Disorders
11/08/2026
Key Highlights Multi-indication precedent: Biogen’s approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single [...]
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares
12/08/2026
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic [...]
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
12/08/2026
GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference ( [...]
Anteris Technologies Announces Results for the Second Quarter of 2026
12/08/2026
MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) a global healthcare company committed to designing, [...]
The Rehab Podcast Refocuses on Benzodiazepine Tapering, Protracted Withdrawal, and BIND
11/08/2026
The Mental Health News Radio Network program, hosted by Mark Leeds, D.O., is turning toward benzodiazepine-related conditions and deprescribing, and is opening guest booking to clinicians, researchers, and people with [...]
COSCIENS Biopharma Inc. Reports Q2 2026 Results
11/08/2026
TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“ COSCIENS ” or the “ Company ”) today reported its financial and operating results for the second quarter ended [...]
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
11/08/2026
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster late-stage drug [...]
Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
11/08/2026
Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Apollomics Announces $10 Million Private Placement Transaction
11/08/2026
FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026
11/08/2026
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, [...]

Pages